Clinical trials: Alzheimer Disease (AD)
Alzheimers Disease
A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)
The primary purpose of the study is to describe the incidence and severity of known adverse events (AEs), including Amyloid-Related Imaging Abnormalities Oedema/Effusion (ARIA-E), Amyloid-Related Imaging…
- Trial name
- NCT07781345
- Testing
- No Intervention
- Where
- 3 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- Eisai Limited
Alzheimer Disease
Memesto Wearable Device for Persons With Dementia
An estimated 70% of the 7.2+ million people in the U.S. with Alzheimer's Disease and Alzheimer's Disease-Related Dementias experience agitation, characterized by poorly organized and purposeless psychomotor activity that…
- Trial name
- NCT05153161
- Testing
- Memesto
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Edgewater Safety Systems, Inc.
Alzheimer Disease, Mild Cognitive Impairment
Transcranial Magnetic Stimulation in Mild Cognitive Impairment and Alzheimer Disease
The investigators reviewed 12 years of clinical use in an outpatient neurology setting of transcranial magnetic stimulation (TMS) in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) to evaluate safety…
- Trial name
- NCT04771845
- Testing
- Transcranial Magnetic Stimulation
- Volunteers
- 73 people
- Sponsor
- The New York Memory Services
Down Syndrome (DS)
Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool
Epigallocatechin-3-gallate (EGCG), the major catechin in green tea, is postulated to modulate dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and amyloid beta precursor protein (APP) gene overexpression in…
- Trial name
- NCT01699711
- Testing
- Epigallocatechin-3-gallate (EGCG)
- Where
- Spain
- Volunteers
- 87 people
- Sponsor
- Parc de Salut Mar
Diabetes, Alzheimer Disease
The Diabetes Prevention Program Outcomes Study AD/ADRD Project
The DPPOS AD/ADRD project will address the overarching question: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2 diabetes (T2D), who are a high-risk group for…
- Conditions
- Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia
- Trial name
- DPPOS-4 (NCT05704309)
- Where
- 27 sites in United States
- Volunteers
- 1,976 people, healthy volunteers welcome
- Sponsor
- Marinella Temprosa
Down Syndrome (DS), Alzheimer's Disease (AD)
Adapting RDAD for DS
The goal of this clinical trial is to observe feasibility and initial efficacy of a remotely delivered exercise and dementia caregiving intervention in older adults with Down syndrome and their caregivers.
- Trial name
- CareFit DS/AD (NCT07425769)
- Testing
- Remote Exercise Sessions, Caregiver Education Sessions
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Kansas Medical Center
Traumatic Brain Injury, Cerebral Palsy
Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy
This prospective observational study collects real world data on participants receiving regenerative therapies administered internationally and delivered intranasally via the Kurve Therapeutics ViaNase device.
- Conditions
- Traumatic Brain Injury, Cerebral Palsy, Hypoxic Ischemic Encephalopathy, Neurologic Disorders
- Trial name
- MuSE-INSIGHT (NCT07521384)
- Where
- Mexico
- Volunteers
- 36 people
- Sponsor
- Healing Hope International
Alzheimer's Disease
Effect of REST in the Alzheimer Disease Continuum
The investigators assume that REST gene polymorphism affects REST protein concentration, and REST protein concentration in peripheral blood is related to cognitive function and hippocampus.
- Trial name
- ERADC (NCT03884023)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Dongzhimen Hospital, Beijing
Alzheimer's Disease
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01689246
- Testing
- TRx0237 150 mg/day, TRx0237 250 mg/day
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 891 people
- Sponsor
- TauRx Therapeutics Ltd
Dementia, Alzheimer Disease
Assessing a Novel Virtual Environment That Assists With Activities of Daily Living
This Phase 1 study looks at how a new videogame-based program can help residents and care partners prepare for ADLs in a fun way with minimal risk, potentially reducing escalating problems associated with ADL completions.
- Conditions
- Dementia, Alzheimer Disease, Neurodegenerative Diseases
- Trial name
- NCT05418296
- Testing
- A novel digital health device
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- mandy
Mild Cognitive Impairment, Neurocardiogenic Syncope
VINCI-AD: An Investigation of Transcutaneous Vagus Nerve Stimulation in Mild Cognitive Impairment.
The VINCI-AD study will investigate the impact of non-invasive vagus nerve stimulation (VNS) on memory in participants with existing mild memory impairment. VNS is a safe, existing treatment, licensed in epilepsy and depression.
- Conditions
- Mild Cognitive Impairment, Neurocardiogenic Syncope, Memory Impairment, Inflammatory Response
- Trial name
- NCT05514756
- Testing
- Active t-VNS, Baseline assessments
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- Tallaght University Hospital
Alzheimer Disease
Phase IIa L-serine Trial for eAD
This is a Phase IIa, randomized, double-blind, placebo controlled trial. Subjects for participation in this study will be identified by the Investigator based on their Clinical Dementia Rating score which will be completed as…
- Trial name
- LSPI-2 (NCT03062449)
- Testing
- L-Serine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Aleksandra Stark
Alzheimer's Disease
Cognitive Rehabilitation in Alzheimer's Disease
This study aims to proof the efficacy of a cognitive rehabilitation program for patients with mild dementia in Alzheimers Disease with respect to activities of daily living.
- Trial name
- NCT02247180
- Testing
- cognitive rehabilitation, standardized cognitive training
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- University of Rostock
Alzheimer Dementia
Exploratory Study for the Validity of QuQu Scale
Examine the construct validity, the group discriminant ability, and the inter-rater reliability of a novel dementia rating scale (QuQu scale: QUick QUestion scale) candidate for the evaluation of patients with Alzheimer Dementia…
- Trial name
- QuQu (NCT02267486)
- Testing
- Standard therapy of Alzheimer Dementia (AD), Observation
- Where
- Japan
- Volunteers
- 972 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Mild Cognitive Impairment, Alzheimer's Disease
Construction of Diagnosis System for Early AD Based on Multi-Modality MRI Technology
One purpose of this study is to construct the diagnosis system for early Alzheimer's disease(AD), which is also called amnestic mild cognitive impairment (aMCI), and then further construct the predictable classifier from aMCI to…
- Trial name
- NCT02353845
- Where
- China
- Volunteers
- 297 people, healthy volunteers welcome
- Sponsor
- XuanwuH 2
Alzheimer Disease
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
The main purpose of the study was to evaluate the safety and tolerability of long-term administration of gantenerumab in participants with AD.
- Trial name
- NCT04339413
- Testing
- Gantenerumab
- Where
- 56 sites in United States, Argentina and 15 more
- Volunteers
- 116 people
- Sponsor
- Hoffmann-La Roche
Alzheimers Disease, Inflammation
Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures
The investigators explore the presence of AD factors beta-amyloid and tau in CSF and plasma to verify AD diagnosis in patients with acute hip fracture. Clinical dementia test is performed prior to operation.
- Conditions
- Alzheimers Disease, Inflammation, Hip Fracture
- Trial name
- ADhipfract (NCT02409082)
- Where
- Sweden
- Volunteers
- 400 people
- Sponsor
- Sahlgrenska University Hospital
Alzheimer s Disease
LiO-AD: Lithium Orotate in Alzheimers Disease Feasibility, Biomarker Engagement, and Clinical Response
The goal of this clinical trial is to assess feasibility, safety, tolerability, and central nervous system target engagement of oral lithium orotate in adults with biomarker-confirmed early Alzheimer's disease.
- Trial name
- LiO-AD (NCT07459959)
- Testing
- Lithium orotate
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Alzheimer Disease
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
This is an open-label, multicenter, rollover study to evaluate the safety, tolerability, and efficacy of long-term administration of open-label gantenerumab in participants with AD who completed Study WN29922 or WN39658, either…
- Trial name
- NCT04374253
- Testing
- Gantenerumab
- Where
- 268 sites in United States, Argentina and 27 more
- Volunteers
- 1,382 people
- Sponsor
- Hoffmann-La Roche
Alzheimer s Disease, Alzheimer Dementia (AD)
Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia
This study evaluates whether the combined treatment of methylphenidate and non-invasive brain stimulation, called intermittent theta burst stimulation, can effectively treat apathy in individuals with Alzheimer's disease or mixed…
- Conditions
- Alzheimer s Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease
- Trial name
- PRIME (NCT07279740)
- Testing
- intermittent theta burst stimulation (iTBS), Methylphenidate (MPH)
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Sunnybrook Health Sciences Centre